Covid 19 Research using Clinical Trials (Home Page)
DoxycyclineWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug917 | Zinc Sulfate Wiki | 0.71 |
| drug244 | DAS181 OL Wiki | 0.71 |
| drug272 | ECCO2R Wiki | 0.71 |
| drug243 | DAS181 COVID-19 Wiki | 0.71 |
| drug242 | DAS181 Wiki | 0.35 |
| drug82 | Azithromycin Wiki | 0.15 |
| drug360 | Hydroxychloroquine Wiki | 0.09 |
| drug616 | Placebo Wiki | 0.07 |
Correlated MeSH Terms (7)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018184 | Paramyxoviridae Infections NIH | 0.41 |
| D012141 | Respiratory Tract Infections NIH | 0.18 |
| D055371 | Acute Lung Injury NIH | 0.11 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.11 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
| D003141 | Communicable Diseases NIH | 0.08 |
| D007239 | Infection NIH | 0.06 |
Correlated HPO Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.29 |
There are 2 clinical trials
Clinical Trials
1 A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting
This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.
NCT04370782 COVID-19 Drug: Hydroxychloroquine Drug: Azithromycin Drug: Zinc Sulfate Drug: Doxycycline
Primary Outcomes
Description: Patients will be assessed on day 5 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial) Time: Day 5Description: Patients will be assessed on day 14 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial) Time: Day 14Description: Patients will be assessed on day 21 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial) Time: Day 21Description: Number of participants hospitalized and/or requiring repeat ER visits related to COVID-19 complications
Measure: Number of participants hospitalized and/or requiring repeat ER visits Time: 21 daysDescription: If hospitalized, number of participants admitted to the ICU, and number of days in the ICU
Measure: ICU Length of Stay Time: Until Discharged up to 30 daysDescription: If placed on ventilator, number of days on a ventilator
Measure: Ventilator Time: Until extubated up to 30 daysSecondary Outcomes
Description: Severity of symptoms evaluated at day 5, day 14, and day 21 scored by the participant for feverishness, sore throat, cough, shortness of breath, myalgias. (0 =none; 1 = mild; 2 = moderate; 3 = severe)
Measure: Severity of symptoms Time: Day 5, Day 14, and Day 21Description: Number of participants with adverse events due to drug regimen
Measure: Number of participants with adverse events due to drug regimen Time: 21 daysDescription: Assess all patients to evaluate for QTc prolongation >500ms
Measure: Number of participants with QTc prolongation >500ms Time: Days 1 thru 5, Day 10, Day 212 Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study
The aim of the study is to compare a treatment with doxycycline vs a placebo as soon as the patient is confirmed COVID-19 + and before the onset of oxygen dependence with the aim of reducing or even abolishing the cytokine explosion and thus the evolution towards a serious form of the disease which can lead to death. Three criteria support the rational use of tetrcycline in COVI-19 (1) The coronaviruses is known to bind to metalloproteases (MMPs) of the host, in particular to ensure viral survival. Tetracyclines are known to chelate zinc from MMPs. Their chelating activity may help inhibit COVID19 infection by limiting its ability to replicate in the host. (2) Tetracyclines may also be able to inhibit the replication of positive-polarity single-stranded RNA viruses, such as COVID19 (demonstrated on the dengue virus). (3) In addition, tetracyclines are modulators of innate immunity (anti-inflammatory activity), a property used in the treatment of inflammatory skin diseases for many years. These modulating effects are noted on several targets of innate immunity: They can decrease the expression of NFKB, the release of inflammatory cytokines such as TNF-α, IL-1β and IL-6, inhibit granulomas inflammatory and free radical release. Tetracyclines could therefore participate in limiting the cytokine release induced by COVID19. Their lipophilic nature and their strong pulmonary penetration could allow them to inhibit viral replication.
NCT04371952 COVID19 Drug: Doxycycline Drug: Placebo
Primary Outcomes
Description: Percentage of patients with clinical worsening (SaO2 ≤ 93%) after at least 48 hours of treatment
Measure: Clinical worsening SaO2 Time: after at least 48 hours of treatmentDescription: Percentage of patients hospitalized after at least 48 hours of experimental treatment
Measure: Patients hospitalized Time: after at least 48 hours of experimental treatmentDescription: Percentage of patients requiring ventilatory assistance
Measure: Ventilatory assistance Time: Day 0 to Day 28Secondary Outcomes
Description: Number of positive SARS-CoV-2 PCR tests on D-1 / D0 and D7 (+/- 2 days)
Measure: Positive SARS-CoV-2 PCR Test Time: Day -1 or day 0 AND Day 7Description: Duration of symptoms (fever, painful symptoms: headache, sore throat, dyspnea)
Measure: Duration of symptoms Time: Day 0 to Day 28Description: Total duration of hospitalization
Measure: Duration of hospitalization Time: From day 0 until to the end of hospitalization or date of death for any cause, whichever came first, assessed up to 3 months after Day0Description: Number and duration of hospitalization in intensive care or reanimation
Measure: Hospitalization intensive care or reanimation Time: From day 0 until to the end of hospitalization or date of death for any cause, whichever came first, assessed up to 3 months after Day0Description: Duration of mechanical ventilatory assistance
Measure: mechanical ventilatory assistance Time: to the end of mechanical ventilatory assistance if any, assessed up to 3 months after Day0Description: Percentage of deaths related to SARS-CoV-2 infection
Measure: Deaths related to SARS-CoV-2 Time: Day 28, or end of hospitalization if any (assessed up to 3 months after Day0)Description: Number of AE / SAE in both arms
Measure: AE / SAE in both arms Time: Day 28, or end of hospitalization if any (assessed up to 3 months after Day0)